The University of Chicago Header Logo

Connection

Olwen Hahn to Cyclooxygenase 2 Inhibitors

This is a "connection" page, showing publications Olwen Hahn has written about Cyclooxygenase 2 Inhibitors.
Connection Strength

0.036
  1. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.